Renuka Roche

Dr. Renuka Roche


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
RRRenuka Roche
Renuka Roche
NONouha Hasan Odeh
Nouha Hasan Odeh
AAAbhay U. Andar
Abhay U. Andar
MTMohan E Tulapurkar
Mohan E Tulapurkar
JRJoseph A Roche
Joseph A Roche
Anti-SARS-CoV-2 vaccines have played a pivotal role in reducing the risk of developing severe illness from COVID-19, thus helping end the COVID-19 global public health emergency after more than three years. Intriguingly, as SARS-CoV-2 variants emerged, individuals who were fully vaccinated did get infected in high numbers, and viral loads in vaccinated individuals were as high as those in the unvaccinated. However, even with high viral loads, vaccinated individuals were significantly less likely to develop severe illness; this begs the question as to whether the main effect of anti-SARS-CoV-2 vaccines is to confer protection against severe illness or immunity against infection. The answer to this question is consequential, not only to the understanding of how anti-SARS-CoV-2 vaccines work, but also to public health efforts against existing and novel pathogens. In this review, we argue that immune system sensitization-desensitization rather than sterilizing immunity may explain vaccine-mediated protection against severe COVID-19 illness even when the SARS-CoV-2 viral load is high. Through the lessons learned from COVID-19, we make the case that in the disease’s aftermath, public health agencies must revisit healthcare policies, including redefining the term “vaccine effectiveness.”

30 April 2026 in Muscles
Verified
Journal Article
Open access
PDF file
BOBana H. Odeh
Bana H. Odeh
AWAmanda Wellman
Amanda Wellman
MAMichael Ameye
Michael Ameye
ZAZachary Atwood
Zachary Atwood
LGLuke Gray
Luke Gray
JRJoseph A Roche
Joseph A Roche
Neuromuscular electrical stimulation (NMES) is integral to studying muscle function in healthy and dystrophic mice. Certain commercial electrodes and laboratory stimulators used for NMES in mice are no longer in production. We developed and/or tested low-cost, open-source alternatives to discontinued commercial standards. We performed two studies—a comparison of electrodes and a comparison of stimulators. In the electrode study, in vivo NMES was applied to the left hindlimb ankle dorsiflexors in healthy C57BL/6J and dysferlin-null BLAJ mice using three electrode types: a previously available commercial electrode, a custom 3D-Printed electrode, and a custom Pen electrode assembled from off-the-shelf components. Twitch and tetanic torque were measured and compared using two-way repeated-measures ANOVA. Twitch torque differed by electrode type (p = 0.031), with lower values observed for the Pen electrode compared with the 3D-Printed electrode (e.g., 573 ± 72 vs. 666 ± 70 mN.mm in C57BL/6J mice), whereas tetanic torque did not differ significantly between electrode types (p = 0.060). In the stimulator study, twitch and tetanic contractions were elicited using the open-source StimJim stimulator and compared with contractions elicited by the discontinued Grass S48 stimulator. Twitch torque was lower with the StimJim (588 ± 107 mN.mm) compared with the Grass S48 (698 ± 116 mN.mm; p < 0.001), whereas tetanic torque values were not statistically different (p = 0.055). These findings indicate that open-source electrodes and stimulators can produce similar maximal tetanic torque under the tested conditions, although differences in twitch torque and stimulation parameters should be considered. These results reflect a methodological validation of accessible tools rather than a formal equivalence analysis.

1 August 2021 in American Journal of Occupational Therapy
Verified
Journal Article
Closed access
PDF file
RRRenuka Roche
Renuka Roche
KGKaitlin Graf
Kaitlin Graf
JRJoseph A. Roche
Joseph A. Roche
Date Presented Accepted for AOTA INSPIRE 2021 but unable to be presented due to online event limitations Individuals with adult-onset muscular dystrophies do not die from the disease but have progressive loss of occupational performance (OP) and quality of life. There is no consistent pathway for referral and access to rehab services. OTs are under-used, even though the greatest need is improvement in OP. The lack of guidelines makes outcomes inconsistent. To work, gene therapies require muscle bulk. OTs may train clients in muscle protection to maintain muscle, giving them a chance at a cure. Primary Author and Speaker: Renuka Roche Additional Authors and Speakers: Kaitlin Graf Contributing Authors: Joseph A. Roche